oncomine precision assay
「oncomine precision assay」熱門搜尋資訊
「oncomine precision assay」文章包含有：「OncominePrecisionAssay」、「OncominePrecisionAssayonIonTorrentGenexusSystem」、「OncominePrecisionAssay」、「OncominePrecisionAssay」、「Oncomine™PrecisionAssayGX」、「RapidgenomicprofilingofcirculatingtumorDNAinnon」、「TargetedNext」、「ThermoFisher'sOncominePrecisionAssaygranted...」
查看更多
Oncomine Precision Assay
https://igbiosystems.com
With the Genexus System, you can go from a biological specimen to a report in just one day. In addition, the system has the ability to analyze small sample ...
Oncomine Precision Assay on Ion Torrent Genexus System
https://www.oncomine.com
The Oncomine Precision Assay content is carefully curated to include all relevant targets and targets of emerging importance in precision oncology clinical ...
Oncomine Precision Assay
https://www.thermofisher.com
A next-generation genomic profiling solution that can allow every laboratory to deliver a genomic profile with a one-day, hands-free workflow.
Oncomine Precision Assay
https://www.q2labsolutions.com
An amplicon-based automated next generation sequencing (NGS) assay that enables quick turnaround genomic profiling of RNA and DNA biomarkers across 50 genes.
Oncomine™ Precision Assay GX
https://www.thermofisher.com
The Ion Torrent Oncomine Precision Assay GX enables the detection of biomarkers in genes such as EGFR, BRAF, KRAS, ALK, ROS1, NTRK, RET, and others fr.
Rapid genomic profiling of circulating tumor DNA in non
https://www.ncbi.nlm.nih.gov
The Oncomine Precision Assay (OPA) is an actionable alterations-focused panel that targeted 50 genes covering 2,769 unique variants including hotspot mutations, ...
Targeted Next
https://www.oncomine.com
The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes based on relevant evidence. Enhanced fusion detection provides broad ...
Thermo Fisher's Oncomine Precision Assay granted ...
https://www.bioanalysis-zone.c
FDA grants Breakthrough Device Designation to Thermo Fisher's assay for identifying low-grade glioma patients eligible for vorasidenib.